Search
Stiripentol
go.drugbank.com/drugs/DB09118ApprovedInvestigationalStiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs. The clinical development and marketing of stiripentol were first delayed due to the drug's...
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsRizatriptan
go.drugbank.com/drugs/DB00953ApprovedInvestigationalRizatriptan is a second-generation triptan [A258918] and a selective 5-HT<sub>1B and 5-HT1D</sub> receptor agonist.
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsAceclofenac
go.drugbank.com/drugs/DB06736ApprovedIn 1991, aceclofenac was developed as an analog of a commonly prescribed NSAID, [DB00586], via chemical modification in effort to improve the gastrointestinal tolerability of the drug.
Mixtures: ZERODOL PCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesPegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigationalWhile agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular
Nelistotug
go.drugbank.com/drugs/DB19334InvestigationalNelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous
MVR-T3011
go.drugbank.com/drugs/DB17378InvestigationalMVR-T3011 is a genetically modified oncolytic Herpes Simplex Virus (HSV-1) with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and the Fab fragment of an anti-human PD-1
ABBV-514
go.drugbank.com/drugs/DB17586InvestigationalABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.[L45464]
Tizanidine
go.drugbank.com/drugs/DB00697ApprovedInvestigationalInitially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesLevacetylmethadol
go.drugbank.com/drugs/DB01227ApprovedWithdrawnLevacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT inte...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates